Survival Benefit of Gemcitabine/Docetaxel Therapy The gem/doce group showed significantly better outcomes, with progression-free, cancer-free, and cancer-specific survival rates 2.6, 2.0, and 3.7 ...

She received the first cycle of GT regimen palliative chemotherapy with gemcitabine 1g/m² (1.6g) on days 1 and 8, and docetaxel 75mg/m² (120mg) on day 1. She developed grade III leukopenia and urinary ...

You have gemcitabine and nab-paclitaxel as cycles of treatment. This means that you have the treatment and then a rest to allow your body to recover. Each cycle of treatment lasts 28 days (4 weeks).

Evidence-based recommendations on durvalumab (Imfinzi) with gemcitabine and cisplatin for treating locally advanced, unresectable, or metastatic biliary tract cancer in adults.. Commercial arrangement ...

Prior to induction BCG, the gemcitabine-docetaxel group had a significantly higher proportion of patients with Ta/Tis (noninvasive) tumors compared with the BCG group (68.8% vs 52.2%), whereas the ...

WASHINGTON, DC—Sequential intravesical gemcitabine-docetaxel (Gem-Doce) for treatment-naïve high-risk nonmuscle-invasive bladder cancer (HR-NMIBC) achieves oncologic outcomes comparable to ...

The safety profile of nivolumab plus gemcitabine–cisplatin was consistent with the established safety profiles of these agents in previous trials involving patients with urothelial carcinoma, ...

Prolonged progression-free survival (PFS) has been demonstrated with intra-arterial (IA) administration of gemcitabine (RenovoGem) in patients with locally advanced pancreatic cancer (LAPC), according ...

Intra-arterial administration of gemcitabine conferred a median PFS benefit of 8 months when compared with standard of care for patients with locally advanced pancreatic cancer, according to ...